基于人工智能的糖尿病视网膜病变筛查在澳大利亚初级保健和内分泌科环境中的有效性:一项实用性试验
在澳大利亚五个全科诊所和内分泌科诊所开展的实用性试验中,纳入863名参与者,使用AI整合的非散瞳眼底相机筛查转诊性糖尿病视网膜病变。AI检测转诊性DR的准确率为93.3%,敏感度83.7%,特异度96.1%,AUC为0.899,86%患者和85%医护人员表示高度满意。
要点
- AI筛查转诊性DR准确率93.3%,敏感度83.7%,特异度96.1%,AUC 0.899。
- AI判读的不可分级图像比例13.4%,低于人工判读的15.6%。
- 86%患者和85%医护人员对AI系统表示高度满意。
核心结论
- AI辅助DR筛查模型在澳大利亚初级保健和内分泌科诊所中准确且受到患者和工作人员的好评。
- 这种机会性筛查模式有望在非眼科环境中加强DR早期发现,可能在大规模上预防DR所致视力丧失。
研究设计与样本
- 实用性试验,在五个地点(包括全科诊所和内分泌科诊所)开展,时间为2021年8月至2023年6月。
- 纳入年龄≥50岁患者以及年龄≥18岁的糖尿病患者,使用AI整合的非散瞳眼底相机进行筛查。
- AI即时分析视网膜图像以检测转诊性DR,检出的转诊性DR或不可分级图像患者被转诊至眼保健专业人员。
- 以金标准人工分级评估AI分级的准确性,并对参与者和照护提供者进行满意度调查。
主要发现
- 共纳入863名参与者,平均(SD)年龄62.6(13.2)岁,53.0%为女性。
- AI系统检测转诊性DR的准确率为93.3%(95%CI:91.4%至95.5%),敏感度83.7%(95%CI:78.2%至88.3%),特异度96.1%(95%CI:94.7%至97.2%),AUC为0.899(95%CI:0.874至0.924)。
- AI判读的不可分级图像比例为13.4%,人工判读为15.6%。
- 86%患者和85%照护提供者对AI系统表示高度满意。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the diagnostic accuracy, feasibility and end-user experiences of an artificial intelligence (AI)-based, automated diabetic retinopathy (DR) screening model in real-world, Australian primary care and endocrinology clinics. METHODS: In a pragmatic trial conducted across five sites including general practice and endocrinology clinics, from August 2021 to June 2023, patients aged ≥50 years, and those aged ≥18 years with diabetes were screened using an AI-integrated, non-mydriatic fundus camera. The AI instantly analysed the retinal images for referable DR. Patients detected with referable DR or ungradable images were referred to eyecare professionals. The accuracy of the AI grading was assessed against gold standard human grading. A satisfaction survey was administered among the participants and care providers. RESULTS: Among 863 participants enrolled (mean (SD) age: 62.6 (13.2) years; 53.0% women), the AI system achieved high accuracy of 93.3% (95% CI: 91.4% to 95.5%) for referable DR detection, with a sensitivity of 83.7% (95% CI: 78.2% to 88.3%), specificity of 96.1% (95% CI: 94.7% to 97.2%) and an area under the receiver operating characteristic curve of 0.899 (95% CI: 0.874 to 0.924). The proportion of ungradable images was lower according to the AI grading (13.4%) compared with human grading (15.6%). Most patients (86%) and care providers (85%) expressed high satisfaction with the AI system. CONCLUSIONS: The AI-assisted DR screening model was accurate and well received by patients and staff in Australian primary care and endocrinology clinics. This opportunistic screening model holds promise for enhancing early DR detection in non-eyecare settings, potentially preventing vision loss due to DR on a considerable scale.
引用
- Joseph S, Wang Y, Drinkwater JJ, et al. Effectiveness of artificial intelligence-based diabetic retinopathy screening in primary care and endocrinology settings in Australia: a pragmatic trial. Br J Ophthalmol. 2025. PMID: 40846450. doi:10.1136/bjo-2025-327447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。